CGIM
MDGL icon

Cannon Global Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cannon Global Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Buy
1,500
+700
+88% +$359K 2.28% 15
2026
Q1 		$419K Buy
800
+100
+14% +$47.8K 0.82% 42
2025
Q4 		$408K Sell
700
-100
-13% -$51.1K 1.02% 41
2025
Q3 		$367K Hold
800
– – 0.55% 51
2025
Q2 		$242K Sell
800
-700
-47% -$209K 0.5% 59
2025
Q1 		$497K Buy
+1,500
New +$493K 0.87% 28

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cannon Global Investment Management's MDGL Position: Q2 2026 in Review

Cannon Global Investment Management increased its Madrigal Pharmaceuticals (MDGL) stake by 88% in Q2 2026, buying an estimated $359K and bringing the position to 1,500 shares worth $805K. The position accounts for 2.28% of the portfolio, ranked #15.

Cannon Global Investment Management first reported a position in MDGL in Q1 2025 and has held it in 6 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Cannon Global Investment Management held 1,500 shares of Madrigal Pharmaceuticals worth $805K as of Q2 2026.
  • Cannon Global Investment Management bought 700 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $359K.
  • Madrigal Pharmaceuticals made up 2.28% of Cannon Global Investment Management's portfolio in Q2 2026, its #15 holding.
  • Cannon Global Investment Management first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.